Becton, Dickinson and Company (NYSE: BDX) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $59.0B. The Maz Rating grades it against the other companies in its sector.
Becton, Dickinson and Company's current Maz Rating and its five factor grades are for members: log in to see them.
At $216.47, Becton, Dickinson and Company trades at 52.2x trailing earnings, 2.9x sales and 2.4x book value, with an EV/EBITDA of 15.9. Over the last twelve months it generated about $20.2B of revenue and $1.1B of net income. It runs a gross margin of 47.3%, an operating margin of 11.6% and a net margin of 5.7%. It shows return on equity of 4.6%, return on invested capital of 4.2% and a free cash flow yield of 4.7%. On the balance sheet: a debt-to-equity ratio of 0.66 and a current ratio of 0.87. Over the past 52 weeks the share price ranged from $140.11 to $220.36, with a beta of 0.28.
Becton, Dickinson and Company pays a dividend yielding 1.84%, with 101% of earnings paid out. Its Maz Dividend Score is 3.77 out of 5, ranked against the other dividend payers in its sector (Safety 1.63, Growth 4.17, Yield 3.97, Consistency 4.76).
34 Wall Street analyst ratings cover the stock: 16 Buy, 16 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Becton, Dickinson and Company (BDX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones and FTSE, and fails AAOIFI and MSCI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 31.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 1.40% / 30% · Interest income / Revenue 0.19% / 5% |
| Fail |
| S&P Global | Debt / Mkt Cap (36m) 31.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 1.40% / 33% · Receivables / Mkt Cap (36m) 5.30% / 49% · Interest income / Revenue 0.19% / 5% | Pass |
|---|
| Dow Jones | Debt / Mkt Cap (24m) 31.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 1.40% / 33.33% · Receivables / Mkt Cap (24m) 5.30% / 33.33% · Interest income / Revenue 0.19% / 5% | Pass |
|---|
| MSCI | Debt / Avg Assets (4Q) 33.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 1.59% / 33.33% · Receivables / Avg Assets (4Q) 4.75% / 33.33% · Interest income / Revenue 0.19% / 5% | Fail |
|---|
| FTSE | Debt / Total Assets 32.2% / 33.33% · (Cash+ST Inv) / Total Assets 1.44% / 33.33% · (Cash+Recv) / Total Assets 6.90% / 33.33% · Interest income / Revenue 0.19% / 5% | Pass |
|---|
It depends on the standard you follow. As of September 2026, Becton, Dickinson and Company (BDX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones and FTSE, and fails AAOIFI and MSCI.
No. Becton, Dickinson and Company is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.19% of each dividend: Becton, Dickinson and Company's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q4 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.